arrow
J

Jonathan H. Soslow

vanderbilt university medical center
H指数:25
被引数:3,125

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

Deramiocel心脏源性细胞疗法治疗晚期杜氏肌营养不良症 (HOPE-3): 一项3期随机、双盲、安慰剂对照试验

2026-07-290
OAAI
Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up

达兰迪斯特罗金(Delandistrogene Moxeparvovec)治疗杜氏肌营养不良症临床试验中的心脏安全性结局,随访时间长达5年

2026-07-010
OAAI
Six-minute activity- 95th centile, a novel Wearable-Derived Clinical Outcome Assessment for Duchenne muscular dystrophy

六分钟活动-第95百分位,一种基于可穿戴设备的新型临床结局评估方法用于杜氏肌营养不良症

2025-11-290
OAAI
Dystrophinopathy in ACTION: The first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective dystrophinopathy registry

Dystrophinopathy在ACTION研究中的表现:高级心脏疗法改善结果网络前瞻性Dystrophinopathy登记研究的首批500名男性受试者

2025-11-080
PRE
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy

关于在杜氏肌营养不良症患者中实施基因治疗及监测的共识推荐与考量

2025-08-230
PRE
Defining Diastolic Dysfunction Post-Fontan: Threshold, Risk Factors, and Associations with Outcomes

定义Fontan术后舒张功能障碍:阈值、危险因素及与预后的关联

2025-07-100
OAAI
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy

Valsartan及早期肥厚型心肌病中的心脏重塑——VANISH随机临床试验的心脏磁共振亚研究

2025-06-010
PRE
Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance

采取行动以检测与杜氏肌营养不良症重组基因转移疗法相关的心肌炎;心脏监测的共识建议

2024-12-200
OA